ESAI.Y Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥10.92 |
| 52 Week High | JP¥21.00 |
| 52 Week Low | JP¥9.31 |
| Beta | -0.062 |
| 1 Month Change | 12.12% |
| 3 Month Change | 3.12% |
| 1 Year Change | -26.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| ESAI.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.3% | 0.9% | 1.6% |
| 1Y | -27.0% | 16.3% | 26.1% |
Return vs Industry: ESAI.Y underperformed the US Pharmaceuticals industry which returned 16% over the past year.
Return vs Market: ESAI.Y underperformed the US Market which returned 26.8% over the past year.
Price Volatility
| ESAI.Y volatility | |
|---|---|
| ESAI.Y Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ESAI.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: ESAI.Y's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,076 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| ESAI.Y fundamental statistics | |
|---|---|
| Market cap | US$12.67b |
| Earnings (TTM) | US$292.25m |
| Revenue (TTM) | US$4.82b |
43.4x
P/E Ratio2.6x
P/S RatioIs ESAI.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESAI.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥749.46b |
| Cost of Revenue | JP¥157.79b |
| Gross Profit | JP¥591.67b |
| Other Expenses | JP¥546.25b |
| Earnings | JP¥45.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 02, 2024
| Earnings per share (EPS) | 158.37 |
| Gross Margin | 78.95% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 19.7% |
How did ESAI.Y perform over the long term?
See historical performance and comparison